What are the key financial results for Eli Lilly from this 10-Q filing?

The provided text is a directory listing of the SEC filing and does not contain specific financial data such as revenue, net income, or earnings per share. To understand the financial results, investors need to access the full 10-Q report, which includes detailed financial statements and the Management's Discussion and Analysis section.

What is the significance of this 10-Q filing for investors?

This 10-Q filing signifies that Eli Lilly is complying with its regulatory obligation to provide quarterly financial updates to investors. It demonstrates transparency and allows stakeholders to monitor the company's ongoing performance and financial health. However, the actual insights depend on the content within the full report.

Where can I find the complete Eli Lilly 10-Q filing from August 1995?

The complete filing can be accessed through the SEC's EDGAR (Electronic Data Gathering, Analysis, and Retrieval) system. The provided text is a directory listing from the EDGAR archives, and typically links to the full document are available from such listings or through the EDGAR company search functionality.

Does this filing indicate any major changes or challenges for Eli Lilly in mid-1995?

The excerpt provided does not detail any specific operational changes, challenges, or strategic shifts. It primarily serves as an index to the filing. A thorough review of the full 10-Q report, particularly the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section, would be necessary to identify any significant developments.

LLY 10-Q Quarterly Report Q2 FY1995 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 10-Q filing for the period ending June 29, 1995, provides a snapshot of its financial performance during the second quarter. While specific financial figures are not detailed in the provided text, the filing indicates the company is operating within its established regulatory framework. Investors should note the company's continued compliance with SEC reporting requirements, which suggests a stable operational environment. Further analysis would require the actual financial statements and management discussion and analysis (MD&A) sections of the report. However, the filing itself signifies that Eli Lilly is actively engaged in public disclosure, a key aspect of corporate governance and investor confidence. Investors are encouraged to seek out the complete filing for a comprehensive understanding of the company's revenue, profitability, and strategic initiatives.

Key Highlights

1Eli Lilly & Co. (LLY) filed its 10-Q Quarterly Report for the period ending June 29, 1995.
2The filing was made on August 7, 1995, adhering to SEC reporting timelines.
3The provided text is a directory listing, indicating the structure and availability of the full filing, rather than a summary of financial results.
4The filing confirms Eli Lilly's commitment to regular financial disclosure for investors.
5Investors can access the complete report through SEC Edgar's filing system.
6No specific financial performance data or significant operational changes are detailed in the excerpt provided.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 1995

Summary

Key Highlights

Frequently Asked Questions